These findings suggest that, in a patient population with ERBB2-positive (also known as HER2-positive) cancer, like the KATHERINE trial population, neoadjuvant THP followed by adjuvant DDAC and T-DM1 for patients with residual disease and followed by H for patients with pCR is associated with the highest health benefits and lowest costs compared with other treatment regimens. Here, ERBB2 is linked to cancer.